Moving Beyond Numbers: How Pharma Can Add Value to Outcome-Based Medicine

Today's guest post comes from Catherine Price. She participated as a panelist at ePharma Summit 2014, is a freelance consultant, journalist and diabetes advocate who’s been living with Type 1 diabetes since 2001. You can find out more about her and her work at diabetesetcetera.com. Follow her on Twitter at @catherine_price.It was an honor to have the chance to give a patient’s perspective at yesterday’s ePharma panel, “Pharma’s New Value Proposition” with fellow panelists Brian Sweet from AstraZeneca, Dave Moore from Cempra, and Jeffrey Farber from Mount Sinai (and moderated by Healthgrades.com’s Brad Graner). Once the conversation began flowing, I found myself overwhelmed by ideas and examples, based on my own experience living with Type 1 diabetes, of how pharma can provide much-needed value to its customers in our evolving healthcare environment. We started the discussion with the Affordable Care Act – or, more specifically, how the switch from fee-for-service to more outcome-based treatment model might affect pharma’s interactions with patients, and what new kinds of “value” can be added as a result. As someone living with an incurable and chronic disease that requires my attention around the clock, I am happy to hear that – at least in theory -- the focus of medical care will be shifting toward long-term outcomes rather than just one-off treatments and appointments. But at the same time, I fear that basing reimbursements on outcomes will create ...
Source: ePharma Summit - Category: Medical Marketing and PR Tags: ePharma ePharma Summit Patient physician dialogue Pharma and patients Pharma interaction with patients Source Type: blogs